BR112018002107A2 - resposta imune potencializada em espécies suínas - Google Patents

resposta imune potencializada em espécies suínas

Info

Publication number
BR112018002107A2
BR112018002107A2 BR112018002107A BR112018002107A BR112018002107A2 BR 112018002107 A2 BR112018002107 A2 BR 112018002107A2 BR 112018002107 A BR112018002107 A BR 112018002107A BR 112018002107 A BR112018002107 A BR 112018002107A BR 112018002107 A2 BR112018002107 A2 BR 112018002107A2
Authority
BR
Brazil
Prior art keywords
immune response
boosted immune
swine species
swine
species
Prior art date
Application number
BR112018002107A
Other languages
English (en)
Inventor
Abraham Albert
Weiss Christian
Keil Daniel
Nickell Jason
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of BR112018002107A2 publication Critical patent/BR112018002107A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção se refere, em geral, a métodos para a indução de uma resposta imune em um sujeito da espécie suína. em particular, uma composição de imunomodulador é utilizada para induzir uma resposta imune para potencializar a capacidade do sujeito para combater patógenos infecciosos.
BR112018002107A 2015-07-31 2016-07-28 resposta imune potencializada em espécies suínas BR112018002107A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199848P 2015-07-31 2015-07-31
PCT/EP2016/067971 WO2017021266A1 (en) 2015-07-31 2016-07-28 Enhanced immune response in porcine species

Publications (1)

Publication Number Publication Date
BR112018002107A2 true BR112018002107A2 (pt) 2018-09-25

Family

ID=56682095

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002107A BR112018002107A2 (pt) 2015-07-31 2016-07-28 resposta imune potencializada em espécies suínas

Country Status (18)

Country Link
US (1) US11439703B2 (pt)
EP (1) EP3328424A1 (pt)
JP (1) JP2018521109A (pt)
KR (1) KR20180036765A (pt)
CN (1) CN108025062A (pt)
AR (1) AR105568A1 (pt)
AU (1) AU2016302436B2 (pt)
BR (1) BR112018002107A2 (pt)
CA (1) CA2993883A1 (pt)
CL (1) CL2018000253A1 (pt)
HK (1) HK1255052A1 (pt)
IL (1) IL256984A (pt)
MX (1) MX2018001251A (pt)
PH (1) PH12018500201A1 (pt)
SG (1) SG10202000891UA (pt)
TW (1) TW201718001A (pt)
WO (1) WO2017021266A1 (pt)
ZA (1) ZA201801338B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001599A2 (pt) 2016-07-26 2019-10-01 Bayer Animal Health Gmbh fertilidade aumentada em espécies bovinas
CA3197650A1 (en) * 2020-10-02 2022-04-07 Celsion Corporation Polynucleotide vaccines and methods of using the same
WO2023224882A1 (en) * 2022-05-17 2023-11-23 Elanco Us Inc. Methods for predicting efficacy of a modified live porcine reproductive and respiratory syndrome virus (prrsv) vaccine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE370740T1 (de) * 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ATE549032T1 (de) 1999-03-26 2012-03-15 Vical Inc Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
HU221664B1 (hu) * 1999-03-31 2002-12-28 MTA Állatorvostudományi Kutatóintézete Élő, szájon át adható Escherichia coli vakcina készítésére alkalmas törzs a sertések választási hasmenésének megelőzésére és a törzs előállítására alkalmas eljárás
US20040002472A1 (en) 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
CA2437899C (en) * 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
PL1605971T3 (pl) 2003-03-26 2010-10-29 Wyeth Llc Kompozycja immunogenna i sposoby
AU2004280143A1 (en) 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20060135457A1 (en) 2004-08-13 2006-06-22 Yvonne Paterson Methods for constructing antibiotic resistance free vaccines
EP2249843A4 (en) * 2008-02-24 2013-05-08 Us Gov Health & Human Serv USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGENIC INFECTIONS
WO2009120811A1 (en) 2008-03-25 2009-10-01 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
US8251111B2 (en) 2008-09-18 2012-08-28 Premium Balloon Accessories, Inc. Balloon inflator
US8465748B2 (en) * 2009-03-30 2013-06-18 Matthias Giese Vaccine compositions and methods containing an immunogen derived from equine arteritis virus
EP2429581B1 (en) * 2009-05-14 2015-08-05 Bayer Intellectual Property GmbH Enhanced immune response in avian species
WO2012084951A1 (en) 2010-12-22 2012-06-28 Bayer Animal Health Gmbh Enhanced immune response in bovine species
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.

Also Published As

Publication number Publication date
PH12018500201A1 (en) 2018-07-30
KR20180036765A (ko) 2018-04-09
EP3328424A1 (en) 2018-06-06
JP2018521109A (ja) 2018-08-02
US11439703B2 (en) 2022-09-13
IL256984A (en) 2018-03-29
TW201718001A (zh) 2017-06-01
WO2017021266A1 (en) 2017-02-09
HK1255052A1 (zh) 2019-08-02
AU2016302436B2 (en) 2022-03-03
MX2018001251A (es) 2018-03-26
US20180326049A1 (en) 2018-11-15
AR105568A1 (es) 2017-10-18
CL2018000253A1 (es) 2018-07-20
SG10202000891UA (en) 2020-03-30
CN108025062A (zh) 2018-05-11
CA2993883A1 (en) 2017-02-09
AU2016302436A1 (en) 2018-02-15
ZA201801338B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
DK3197489T3 (da) Fremgangsmåder og sammensætninger til at fremkalde beskyttende immunitet over for human immundefekt virusinfektion
BR112017010177A2 (pt) composição para tratamento de tecido
BR112017002761A2 (pt) composições anti-metanogênicas e usos das mesmas
BR112019005329A2 (pt) composições de oligossacarídeos de leite humano purificadas
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
BR112018076715A2 (pt) composição de alimento compreendendo uma protease ácida.
MA40911A (fr) Compositions de piégeage d'oxygène ne nécessitant pas de période d'induction
DK3380120T3 (da) Immunstimulerende sammensætninger
MX2017016401A (es) Composiciones inmunogenas.
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
MX2018000091A (es) Virus de la enteritis del pato y usos del mismo.
BR112018002107A2 (pt) resposta imune potencializada em espécies suínas
IL254698A0 (en) A vaccine based on the recombinant Jarl Lin mumps virus 2
BR112017028121A2 (pt) métodos para modular moléculas de vigilância de dna citosólico
BR112017025316A2 (pt) estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
MX2017009796A (es) Mdv1 recombinantes y usos de los mismos.
BR112018003714A2 (pt) composições de ácido de peso aumentado que compreendem aminoácidos
BR112017028602A2 (pt) células dendríticas devidamente ativadas que induzem uma resposta imune antitumoral aperfeiçoada ou aumentada
BR112017028052A2 (pt) peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina
MX2018003173A (es) Vacunas de salmonella choleraesuis-salmonella typhimurium.
ES2570433A1 (es) Utilizacion de proantocianidinas para la supresion del apetito o induccion de la saciedad
BR112016019395A2 (pt) composição
EA201991165A1 (ru) Способы усиления иммунного ответа с помощью эверолимуса, дактолисиба или обоих
BR112018002660A2 (pt) ?composição imunogênica, e, método para induzir uma resposta imune a staphylococcus aureus?

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]